Zealand Pharma reports impressive 2025 performance due to collaboration with Roche

Investing.com - Zealand Pharma A/S (CSE:ZELA) announced its full-year financial results for 2025 on Thursday, highlighting a transformative year driven by a historic partnership with Roche on the weight-loss drug petrelintide (a glucagon-like peptide-1 analog).

The company is currently in what it calls its “most catalyst-rich year in company history,” with key clinical data expected to be released throughout 2026.

Zealand reported revenue of 9.22 billion Danish kroner in 2025, up from only 63 million Danish kroner in 2024, primarily due to the collaboration with Roche. Net operating expenses after other operational items totaled 2.1 billion Danish kroner, compared to 1.32 billion Danish kroner in 2024.

The company’s cash position at year-end was strong at 15.11 billion Danish kroner, up from 9.02 billion Danish kroner at the end of 2024.

Zealand Pharma President and CEO Adam Steensberg stated, “Building on significant progress in 2025, we reached a historic partnership with Roche on petrelintide and made strong clinical advances in our key programs. We are now entering a 2026 that is rich in catalysts and of decisive importance.”

“We look forward to the upcoming Phase 2 data for ZUPREME-1 with petrelintide, the potential initiation of Phase 3 development for petrelintide, and all key trial results for survodutide in the SYNCHRONIZE obesity program.”

For 2026, Zealand expects net operating expenses after other operational items to be between 2.7 billion and 3.3 billion Danish kroner, mainly driven by clinical advancement of the petrelintide series and research aligned with its “Metabolic Frontier 2030” strategy.

The company also has the potential to receive up to $700 million in milestone payments from Roche in 2026.

Zealand’s obesity pipeline continues to advance, with Phase 2 data for petrelintide expected in the first quarter of 2026, and plans to initiate a full Phase 3 program in the second half of the year.

Additionally, partner Boehringer Ingelheim is expected to announce results from all key trials of the Phase 3 SYNCHRONIZE program for survodutide throughout 2026.

The company also announced plans to establish a research facility in Boston in 2026, combining its peptide expertise with advanced automation and AI-driven drug discovery to accelerate the development of new metabolic health therapies.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.